Exploiting sp(2) -Hybridisation in the Development of Potent 1,5-α-l-Arabinanase Inhibitors.
Identifieur interne : 000C56 ( PubMed/Checkpoint ); précédent : 000C55; suivant : 000C57Exploiting sp(2) -Hybridisation in the Development of Potent 1,5-α-l-Arabinanase Inhibitors.
Auteurs : Travis Coyle [Australie] ; Aleksandra W. Debowski [Australie] ; Annabelle Varrot [France] ; Keith A. Stubbs [Australie]Source :
- Chembiochem : a European journal of chemical biology [ 1439-7633 ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- antagonistes et inhibiteurs : Glycosidases.
- synthèse chimique : Antienzymes, Réactifs chromogènes.
- Cristallographie aux rayons X, Fusarium, Modèles moléculaires, Relation structure-activité.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Glycoside Hydrolases.
- chemical , chemical synthesis : Chromogenic Compounds, Enzyme Inhibitors.
- chemistry : Fusarium.
- Crystallography, X-Ray, Models, Molecular, Structure-Activity Relationship.
Abstract
The synthesis of potent inhibitors of GH93 arabinanases as well as a synthesis of a chromogenic substrate to measure GH93 arabinanase activity are described. An insight into the reasons behind the potency of the inhibitors was gained through X-ray crystallographic analysis of the arabinanase Arb93A from Fusarium graminearum. These compounds lay a foundation for future inhibitor development as well as for the use of the chromogenic substrate in biochemical studies of GH93 arabinanases.
DOI: 10.1002/cbic.201700073
PubMed: 28266777
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28266777Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Exploiting sp(2) -Hybridisation in the Development of Potent 1,5-α-l-Arabinanase Inhibitors.</title><author><name sortKey="Coyle, Travis" sort="Coyle, Travis" uniqKey="Coyle T" first="Travis" last="Coyle">Travis Coyle</name><affiliation wicri:level="1"><nlm:affiliation>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009</wicri:regionArea><wicri:noRegion>6009</wicri:noRegion></affiliation></author><author><name sortKey="Debowski, Aleksandra W" sort="Debowski, Aleksandra W" uniqKey="Debowski A" first="Aleksandra W" last="Debowski">Aleksandra W. Debowski</name><affiliation wicri:level="1"><nlm:affiliation>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009</wicri:regionArea><wicri:noRegion>6009</wicri:noRegion></affiliation></author><author><name sortKey="Varrot, Annabelle" sort="Varrot, Annabelle" uniqKey="Varrot A" first="Annabelle" last="Varrot">Annabelle Varrot</name><affiliation wicri:level="4"><nlm:affiliation>CERMAV, Université Grenoble Alpes, CNRS, 38000, Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CERMAV, Université Grenoble Alpes, CNRS, 38000, Grenoble</wicri:regionArea><placeName><settlement type="city">Grenoble</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName><orgName type="university">Université Grenoble-Alpes</orgName></affiliation></author><author><name sortKey="Stubbs, Keith A" sort="Stubbs, Keith A" uniqKey="Stubbs K" first="Keith A" last="Stubbs">Keith A. Stubbs</name><affiliation wicri:level="1"><nlm:affiliation>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009</wicri:regionArea><wicri:noRegion>6009</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28266777</idno><idno type="pmid">28266777</idno><idno type="doi">10.1002/cbic.201700073</idno><idno type="wicri:Area/PubMed/Corpus">000B55</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B55</idno><idno type="wicri:Area/PubMed/Curation">000B52</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B52</idno><idno type="wicri:Area/PubMed/Checkpoint">000B52</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B52</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Exploiting sp(2) -Hybridisation in the Development of Potent 1,5-α-l-Arabinanase Inhibitors.</title><author><name sortKey="Coyle, Travis" sort="Coyle, Travis" uniqKey="Coyle T" first="Travis" last="Coyle">Travis Coyle</name><affiliation wicri:level="1"><nlm:affiliation>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009</wicri:regionArea><wicri:noRegion>6009</wicri:noRegion></affiliation></author><author><name sortKey="Debowski, Aleksandra W" sort="Debowski, Aleksandra W" uniqKey="Debowski A" first="Aleksandra W" last="Debowski">Aleksandra W. Debowski</name><affiliation wicri:level="1"><nlm:affiliation>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009</wicri:regionArea><wicri:noRegion>6009</wicri:noRegion></affiliation></author><author><name sortKey="Varrot, Annabelle" sort="Varrot, Annabelle" uniqKey="Varrot A" first="Annabelle" last="Varrot">Annabelle Varrot</name><affiliation wicri:level="4"><nlm:affiliation>CERMAV, Université Grenoble Alpes, CNRS, 38000, Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CERMAV, Université Grenoble Alpes, CNRS, 38000, Grenoble</wicri:regionArea><placeName><settlement type="city">Grenoble</settlement><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName><orgName type="university">Université Grenoble-Alpes</orgName></affiliation></author><author><name sortKey="Stubbs, Keith A" sort="Stubbs, Keith A" uniqKey="Stubbs K" first="Keith A" last="Stubbs">Keith A. Stubbs</name><affiliation wicri:level="1"><nlm:affiliation>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009</wicri:regionArea><wicri:noRegion>6009</wicri:noRegion></affiliation></author></analytic><series><title level="j">Chembiochem : a European journal of chemical biology</title><idno type="eISSN">1439-7633</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chromogenic Compounds (chemical synthesis)</term><term>Crystallography, X-Ray</term><term>Enzyme Inhibitors (chemical synthesis)</term><term>Fusarium (chemistry)</term><term>Glycoside Hydrolases (antagonists & inhibitors)</term><term>Models, Molecular</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antienzymes (synthèse chimique)</term><term>Cristallographie aux rayons X</term><term>Fusarium ()</term><term>Glycosidases (antagonistes et inhibiteurs)</term><term>Modèles moléculaires</term><term>Relation structure-activité</term><term>Réactifs chromogènes (synthèse chimique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Glycoside Hydrolases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Chromogenic Compounds</term><term>Enzyme Inhibitors</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Glycosidases</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Fusarium</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antienzymes</term><term>Réactifs chromogènes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Crystallography, X-Ray</term><term>Models, Molecular</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Cristallographie aux rayons X</term><term>Fusarium</term><term>Modèles moléculaires</term><term>Relation structure-activité</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The synthesis of potent inhibitors of GH93 arabinanases as well as a synthesis of a chromogenic substrate to measure GH93 arabinanase activity are described. An insight into the reasons behind the potency of the inhibitors was gained through X-ray crystallographic analysis of the arabinanase Arb93A from Fusarium graminearum. These compounds lay a foundation for future inhibitor development as well as for the use of the chromogenic substrate in biochemical studies of GH93 arabinanases.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28266777</PMID><DateCreated><Year>2017</Year><Month>03</Month><Day>07</Day></DateCreated><DateCompleted><Year>2017</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2017</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-7633</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Chembiochem : a European journal of chemical biology</Title><ISOAbbreviation>Chembiochem</ISOAbbreviation></Journal><ArticleTitle>Exploiting sp(2) -Hybridisation in the Development of Potent 1,5-α-l-Arabinanase Inhibitors.</ArticleTitle><Pagination><MedlinePgn>974-978</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cbic.201700073</ELocationID><Abstract><AbstractText>The synthesis of potent inhibitors of GH93 arabinanases as well as a synthesis of a chromogenic substrate to measure GH93 arabinanase activity are described. An insight into the reasons behind the potency of the inhibitors was gained through X-ray crystallographic analysis of the arabinanase Arb93A from Fusarium graminearum. These compounds lay a foundation for future inhibitor development as well as for the use of the chromogenic substrate in biochemical studies of GH93 arabinanases.</AbstractText><CopyrightInformation>© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coyle</LastName><ForeName>Travis</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Present address: School of Chemistry, University College Dublin, Stillorgan Road, Belfield, Dublin, 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debowski</LastName><ForeName>Aleksandra W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varrot</LastName><ForeName>Annabelle</ForeName><Initials>A</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-6667-8162</Identifier><AffiliationInfo><Affiliation>CERMAV, Université Grenoble Alpes, CNRS, 38000, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stubbs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-6899-402X</Identifier><AffiliationInfo><Affiliation>School of Molecular Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA, 6009, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Chembiochem</MedlineTA><NlmUniqueID>100937360</NlmUniqueID><ISSNLinking>1439-4227</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002863">Chromogenic Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.-</RegistryNumber><NameOfSubstance UI="D006026">Glycoside Hydrolases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.55</RegistryNumber><NameOfSubstance UI="C019713">alpha-N-arabinofuranosidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002863" MajorTopicYN="N">Chromogenic Compounds</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005670" MajorTopicYN="N">Fusarium</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006026" MajorTopicYN="N">Glycoside Hydrolases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">arabinanases</Keyword><Keyword MajorTopicYN="N">carbamate</Keyword><Keyword MajorTopicYN="N">chromogenic substrate</Keyword><Keyword MajorTopicYN="N">enzyme inhibitors</Keyword><Keyword MajorTopicYN="N">hydroximolactone</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28266777</ArticleId><ArticleId IdType="doi">10.1002/cbic.201700073</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Grenoble</li></settlement><orgName><li>Université Grenoble-Alpes</li></orgName></list><tree><country name="Australie"><noRegion><name sortKey="Coyle, Travis" sort="Coyle, Travis" uniqKey="Coyle T" first="Travis" last="Coyle">Travis Coyle</name></noRegion><name sortKey="Debowski, Aleksandra W" sort="Debowski, Aleksandra W" uniqKey="Debowski A" first="Aleksandra W" last="Debowski">Aleksandra W. Debowski</name><name sortKey="Stubbs, Keith A" sort="Stubbs, Keith A" uniqKey="Stubbs K" first="Keith A" last="Stubbs">Keith A. Stubbs</name></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Varrot, Annabelle" sort="Varrot, Annabelle" uniqKey="Varrot A" first="Annabelle" last="Varrot">Annabelle Varrot</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000C56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28266777
|texte= Exploiting sp(2) -Hybridisation in the Development of Potent 1,5-α-l-Arabinanase Inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28266777" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |